Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect ... memory function in a well-established mouse model of Alzheimer’s disease.

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

Caviness Distinguished Professor of Medicine and Director of the UNC Diabetes Care Center. “Semaglutide has been a main stay of our efforts to reduce heart attack and stroke in people with diabetes.

Perspective from Susan P. Mollan, MBChB, FRCOphth, PhD In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy ...

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...